The faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes

Lv, Longxian; Jiang, Huiyong; Chen, Yanfei; Gu, Silan; Xia, Jiafeng; Zhang, Hua; Lu, Yingfeng; Ren, Yan; Li, Lanjuan

doi:10.1016/j.aca.2021.338267

Cited by 71 publications

(80 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results corroborate the alterations recently reported in the faecal metabolome for COVID-19 patients 37 . However, the question of whether COVID-19-related intestinal lesions are the result of a secondary response following systemic in ammation, of primary intestinal infection, or of the combined consequences of both mechanisms, remains open.…”

Section: Discussionsupporting

confidence: 92%

Taxonomical and functional changes in COVID-19 faecal microbiome are related to SARS-CoV-2 faecal load

Armengaud

Grenga

Pible³

et al. 2021

Preprint

View full text Add to dashboard Cite

Since the beginning of the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the gastro-intestinal (GI) tract has emerged as an important organ influencing the propensity to and potentially severity of the related COVID-19 disease. However, the contribution of the SARS-CoV-2 intestinal infection on COVID-19 pathogenesis remains to be clarified. In this exploratory study, we evidenced that alterations in the composition of the gut microbiota depends on the levels of SARS-CoV-2 RNA in the gastrointestinal tract but not on the presence of SARS-CoV-2 in the respiratory tract, COVID-19 severity and GI symptoms. Altered molecular functions in the microbiota profiles of high SARS-CoV-2 RNA level faeces as established by metaproteomics highlight mechanisms that may contribute to vicious cycles. Uncovering the role of this gut microbiota dysbiosis could drive the investigation of alternative therapeutic strategies to favour the clearance of the virus and potentially mitigate the effect of SARS-CoV-2 infection.

show abstract

Section: Discussionsupporting

confidence: 92%

Taxonomical and functional changes in COVID-19 faecal microbiome are related to SARS-CoV-2 faecal load

Armengaud

Grenga

Pible³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The metabolomic sample was prepared from 0.2 g of feces as described previously ( 50 , 51 ). Metabolites were assayed by gas chromatography-mass spectrometry (GC-MS) using an Agilent 7890A GC system coupled to an Agilent 5975C inert mass selective detector system (Agilent Technologies, Santa Clara, CA).…”

Section: Methodsmentioning

confidence: 99%

Lactobacillus acidophilus LA14 Alleviates Liver Injury

Yao

Ren

et al. 2021

mSystems

Self Cite

View full text Add to dashboard Cite

show abstract

“…The metabolome was assayed as described previously ( 16 , 17 ). Briefly, 20 mg of feces or 200 μL of the serum was added to 800 μL of precooled chromatography grade methanol (Sigma-Aldrich, St. Louis, MO, USA).…”

Section: Methodsmentioning

confidence: 99%

Mechanism of the Immunomodulatory Effect of the Combination of Live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus on Immunocompromised Rats

et al. 2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Immunodeficiency is a very common condition in suboptimal health status and during the development or treatment of many diseases. Recently, probiotics have become an important means for immune regulation. The present study aimed to investigate the mechanism of the immunomodulatory effect of a combination of live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus (CBLEB), which is a drug used by approximately 10 million patients every year, on cyclophosphamide-immunosuppressed rats. Cyclophosphamide (40 mg/kg) was intraperitoneally injected to induce immunosuppression in a rat model on days 1, 2, 3, and 10. Starting from day 4, the rats were continuously gavaged with CBLEB solution for 15 days. The samples were collected to determine routine blood test parameters, liver and kidney functions, serum cytokine levels, gut microbiota, fecal and serum metabolomes, transcriptomes, and histopathological features. The results indicated that CBLEB treatment reduced cyclophosphamide-induced death, weight loss, and damage to the gut, liver, spleen, and lungs and eliminated a cyclophosphamide-induced increase in the mean hemoglobin content and GGT, M-CSF, and MIP-3α levels and a decrease in the red blood cell distribution width and total protein and creatinine levels in the blood. Additionally, CBLEB corrected cyclophosphamide-induced dysbiosis of the gut microbiota and eliminated all cyclophosphamide-induced alterations at the phylum level in rat feces, including the enrichment in Proteobacteria, Fusobacteriota, and Actinobacteriota and depletion of Spirochaetota and Cyanobacteria. Furthermore, CBLEB treatment alleviated cyclophosphamide-induced alterations in the whole fecal metabolome profile, including enrichment in 1-heptadecanol, succinic acid, hexadecane-1,2-diol, nonadecanoic acid, and pentadecanoic acid and depletion of benzenepropanoic acid and hexane. CBLEB treatment also alleviated cyclophosphamide-induced enrichment in serum D-lyxose and depletion of serum succinic acid, D-galactose, L-5-oxoproline, L-alanine, and malic acid. The results of transcriptome analysis indicated that the mechanism of the effect of CBLEB was related to the induction of recovery of cyclophosphamide-altered carbohydrate metabolism and signal transduction. In conclusion, the present study provides an experimental basis and comprehensive analysis of application of CBLEB for the treatment of immunodeficiency.

show abstract

The faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes

Cited by 71 publications

References 33 publications

Taxonomical and functional changes in COVID-19 faecal microbiome are related to SARS-CoV-2 faecal load

Taxonomical and functional changes in COVID-19 faecal microbiome are related to SARS-CoV-2 faecal load

Lactobacillus acidophilus LA14 Alleviates Liver Injury

Mechanism of the Immunomodulatory Effect of the Combination of Live Bifidobacterium, Lactobacillus, Enterococcus, and Bacillus on Immunocompromised Rats

Contact Info

Product

Resources

About